Abstract
Current limitation in cancer genomic studies is a lack of the integration of various omics data generated through next generation sequencing technologies, as well as a lack of the sounding and comprehensive epigenomic and genomic information about a particular cancer cell type. In this review, we will discuss main aspects of current genomics research with its application in cancer topics. We will first overview the next-generation sequencing technologies, then outline the major computational approaches, particularly focusing on ChIP-based omics data, and list several remaining open questions facing computational biologists, further present regulatory network analysis inferred from the ChIP-based omics data; finally implicate the clinical outcomes from the network and pathway analysis.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 277-283 |
| Number of pages | 7 |
| Journal | Cancer Letters |
| Volume | 340 |
| Issue number | 2 |
| DOIs | |
| State | Published - Nov 1 2013 |
Keywords
- Cancer omics
- Clinical outcomes
- Next generation sequencing
- Regulatory networks
ASJC Scopus subject areas
- Oncology
- Cancer Research
Fingerprint
Dive into the research topics of 'Cancer omics: From regulatory networks to clinical outcomes'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS